MCID: AGR002
MIFTS: 44

Agoraphobia malady

Category: Mental diseases

Aliases & Classifications for Agoraphobia

About this section

Aliases & Descriptions for Agoraphobia:

Name: Agoraphobia 11 50 39 13 68
 
Fear of Open Spaces 11

Classifications:



External Ids:

Disease Ontology11 DOID:593
ICD1030 F40.0, F40.00
MeSH39 D000379
NCIt45 C34362

Summaries for Agoraphobia

About this section
Disease Ontology:11 A phobic disorder involving the specific anxiety about being in a place or situation where escape is difficult or embarrassing or where help may be unavailable.

MalaCards based summary: Agoraphobia, also known as fear of open spaces, is related to personality disorder and panic disorder. An important gene associated with Agoraphobia is HTR1A (5-Hydroxytryptamine Receptor 1A), and among its related pathways are Neurotransmitter Clearance In The Synaptic Cleft and Paroxetine Pathway, Pharmacokinetics. The drug alprazolam has been mentioned in the context of this disorder. Affiliated tissues include cortex, thyroid and brain, and related mouse phenotypes are cardiovascular system and behavior/neurological.

Wikipedia:71 Agoraphobia is an anxiety disorder characterized by symptoms of anxiety in situations where the person... more...

Related Diseases for Agoraphobia

About this section

Diseases related to Agoraphobia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 72)
idRelated DiseaseScoreTop Affiliating Genes
1personality disorder30.0HTR1A, MAOA, SLC6A2, SLC6A4
2panic disorder11.6
3anxiety disorder11.2
4dry eye syndrome10.2HTR1A, SLC6A4
5anodontia10.2HTR1A, SLC6A4
6apperceptive agnosia10.2HTR1A, SLC6A4
7social phobia10.2
8conjunctival pigmentation10.2MAOA, SLC6A4
9waardenburg's syndrome10.2HTR1A, SLC6A4
10pyromania10.2MAOA, SLC6A4
11luxation of globe10.2HTR1A, SLC6A4
12strongyloidiasis10.2MAOA, SLC6A4
13intrahepatic gall duct cancer10.2MAOA, SLC6A4
14primary angle-closure glaucoma10.1HTR1A, SLC6A4
15renpenning syndrome10.1HTR1A, MAOA, SLC6A4
16tinea pedis10.1HTR1A, MAOA, SLC6A4
17chronic eosinophilic pneumonia10.1HTR1A, MAOA, SLC6A4
18hypoglycemic coma10.1HTR1A, MAOA, SLC6A4
19multiple personality disorder10.1HTR1A, MAOA, SLC6A4
20hepatitis b reinfection following liver transplantation10.1HTR1A, MAOA, SLC6A4
21cecal benign neoplasm10.1HTR1A, MAOA, SLC6A4
22lichen disease10.1HTR1A, MAOA, SLC6A4
23generalized anxiety disorder10.1
24retinoblastoma10.1HTR1A, MAOA, SLC6A4
25cytomegalic congenital adrenal hypoplasia10.1MAOA, SLC6A4
26carotid stenosis10.1MAOA, SLC6A4
27mandibular cancer10.1HTR1A, SLC6A4
28microcephaly 13, primary, autosomal recessive10.1HTR1A, MAOA, SLC6A4
29ornithosis10.1MAOA, PTK7, SLC6A4
30obsessive-compulsive disorder10.1
31atrial fibrillation, familial, 1010.1HTR1A, MAOA, SLC6A4
32schizoid personality disorder10.0PIR, SLC6A4
33antisocial personality disorder10.0HTR1A, PIR
34nephrogenic adenoma of the urethra10.0SLC6A2, SLC6A4
35hypereosinophilic syndrome10.0MAOA, OPRK1, SLC6A4
36colorectal adenocarcinoma10.0MAOA, SLC6A2, SLC6A4
37transmitted_by9.9OPRK1, SLC6A4
38neurogenic bladder9.9MAOA, PIR, SLC6A4
39preeclampsia/eclampsia 59.9HTR1A, MAOA, OPRK1, SLC6A4
40eating disorder9.9
41postencephalitic parkinson disease9.9HTR1A, MAOA, SLC6A2, SLC6A4
42keratosis9.9HTR1A, MAOA, SLC6A2, SLC6A4
43benign epilepsy with centrotemporal spikes9.9HTR1A, MAOA, SLC6A2, SLC6A4
44ellis-van creveld syndrome9.9HTR1A, MAOA, SLC6A2, SLC6A4
45separation anxiety disorder9.8
46thyroiditis9.8
47hypochondriasis9.7
48melancholia9.7
49irritable bowel syndrome9.7
50hepatitis d9.7HTR1A, MAOA, PTK7, SLC6A2, SLC6A4

Graphical network of the top 20 diseases related to Agoraphobia:



Diseases related to agoraphobia

Symptoms & Phenotypes for Agoraphobia

About this section

MGI Mouse Phenotypes related to Agoraphobia according to GeneCards Suite gene sharing:

41
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053858.3CCKBR, HTR1A, MAOA, PTK7, SLC6A2, SLC6A4
2MP:00053868.3CCKBR, GRPR, HTR1A, MAOA, OPRK1, SLC6A2
3MP:00053767.8CCKBR, GRPR, HTR1A, MAOA, OPRK1, SLC6A2
4MP:00036316.9CCKBR, HTR1A, MAOA, OPRK1, PTK7, SLC6A2

Drugs & Therapeutics for Agoraphobia

About this section

Drugs for Agoraphobia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Alprazolamapproved, illicit, investigationalPhase 4, Phase 16928981-97-72118
Synonyms:
28981-97-7
611026_ALDRICH
611026_FLUKA
8-Chloro-1-methyl-6-(phenyl-d5)-4H-(1,2,4)triazolo[4,3-a][1,4]benzodiazepine
8-Chloro-1-methyl-6-phenyl-4H-S-triazolo(4,3-a)(1,4)benzodiazepine
8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine
8-Chloro-1-methyl-6-phenyl-4H-s-triazolo(4,3-alpha)(1,4)benzodiazepine
8-Chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine
A6551_FLUKA
A6551_SIGMA
A8800_SIGMA
AC-18721
AC1L1CYL
AKOS005066050
AP-1002
AZ-002
Alcelam
Algad
Alpaz
Alphapharm Brand of Alprazolam
Alplax
Alpram
Alprax
Alprazolam
Alprazolam (JP15/USP/INN)
Alprazolam Alphapharm Brand
Alprazolam Apotex Brand
Alprazolam Kenral Brand
Alprazolam Novopharm Brand
Alprazolam Nu-Pharm Brand
Alprazolam Orion Brand
Alprazolam Pfizer Brand
Alprazolam Temmler Brand
Alprazolam [USAN:INN:BAN:JAN]
Alprazolam extended release tablets
Alprazolam intensol
Alprazolam solution
Alprazolam-d5
Alprazolamum
Alprazolamum [INN-Latin]
Alprazolan
Alpronax
Alprox
Alviz
Alzam
Alzolam
Alzon
Anpress
Apo Alpraz
Apo-Alpraz
ApoAlpraz
Apotex Brand of Alprazolam
Arzneimittelwerk Dresden Brand of Alprazolam
Azor
BIDD:GT0475
BIDD:PXR0150
BRN 1223125
Bestrol
Bio-0790
C06817
CHEBI:2611
CHEMBL661
CID2118
CPD000149316
Cassadan
Constan
D 65MT
D-65MT
D000525
D00225
D65MT
DB00404
DEA No. 2882
EINECS 249-349-2
Esparon
Frontal
Gen-Alprazolan
HMS2051A10
 
HSDB 7207
Helex
I14-7472
Intensol
Kenral Brand of Alprazolam
Ksalol
LS-156344
MLS000559000
MLS000759485
Mialin
MolPort-002-507-836
NCGC00159466-02
NCGC00159466-03
Neurol
Niravam
Novo Alprazol
Novo-Alprazol
NovoAlprazol
Novopharm Brand of Alprazolam
Nu Alpraz
Nu Pharm Brand of Alprazolam
Nu-Alpraz
Nu-Pharm Brand of Alprazolam
NuAlpraz
Orion Brand of Alprazolam
Panistat
Panix
Pfizer Brand of Alprazolam
Pharnax
Prazam
Prazolan
Prinox
Ralozam
Relaxol
Restyl
SAM001246696
SMR000149316
STK590494
Solanax
Staccato-alprazolam
TGAR01P
TUS-1
Tafil
Tafil D
Temmler Brand of Alprazolam
Tensivan
Tranax
Trankimazin
Tranquinal
Tricalma
Tus 1
U 31889
U-31,889
U-31889
U31,889
UNII-YU55MQ3IZY
Unilan
Valeans
Xanagis
Xanax
Xanax (TN)
Xanax TS
Xanax XR
Xanolam
Xanor
ZINC00000903
Zacetin
Zanapam
Zaxan
Zenax
Zolam
Zolan
Zolarem
Zoldac
Zoldax
Zopax
Zopic
Zotran
alprazolam
nchembio747-comp35
2
SertralineapprovedPhase 429979617-96-268617
Synonyms:
(+)-Sertraline
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine
(1S,4S)-sertraline
(1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
(1S-cis)-1,2,3,4-tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine
(1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine
79559-97-0 (Hydrochloride)
79617-96-2
AB00514002
AB1004870
AC-15639
AC1L2A41
AC1Q3O5N
AC1Q3XJU
Apo-Sertraline
BIDD:GT0768
BIDD:PXR0193
BPBio1_001285
BRD-K82036761-003-02-1
BRN 5753709
BSPBio_001167
BSPBio_002698
C07246
C17H17Cl2N
CHEBI:9123
CHEMBL809
CID68617
Cp 51974
D02360
DB01104
DB08567
FT-0081122
HSDB 7037
KBio3_001918
 
KBioGR_001724
LS-94179
Lustral
MLS001195647
MLS002222308
MolPort-002-885-860
NCGC00092386-03
NCGC00092386-04
NCGC00092386-05
NCGC00092386-06
NCGC00092386-07
NCGC00092386-08
NCGC00092386-09
Prestwick3_001014
SMR000596516
SPBio_000385
SRE
Sertralina
Sertralina [Spanish]
Sertraline
Sertraline (INN)
Sertraline Hydrochloride
Sertraline [INN:BAN]
Sertraline [Zoloft]
Sertraline hydrochloride
Sertralinum
Sertralinum [Latin]
Spectrum2_000493
Spectrum3_001079
Spectrum4_001232
Sultamicillin Tosylate
UNII-QUC7NX6WMB
Zoloft
cis-(+)-sertraline
sertraline
sertraline (Zoloft)
3
Clonazepamapproved, illicitPhase 4321622-61-32802
Synonyms:
1,3-Dihydro-5-(o-chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2-one
1,3-Dihydro-7-nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one
1,3-dihydro-7-Nitro-5-(2-chlorophenyl)-2H-1,4.benzodiazepin-2-one
106955-87-7
1622-61-3
5-(2-Chloro-phenyl)-7-nitro-1,3-dihydro-benzo[e][1,4]diazepin-2-one
5-(2-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one
5-(2-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
5-(2-Chlorophenyl)-7-nitro-1H-benzo[e][1,4]diazepin-2(3H)-one
5-(2-Chlorophenyl)-7-nitro-3H-1,4-benzodiazepin-2(1H)-one
5-(2-chlorophenyl)-7-nitro-1,3-dihydro-1,4-benzodiazepin-2-one
5-(O-Chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one
5-(o-Chlorophenyl)-7-nitro-1H-1,4-benzodiazepin-2(3H)-one
5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-one
5-24-04-00351 (Beilstein Handbook Reference)
7-Nitro-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one
AC-15733
AC1L1EI2
Alti-Clonazepam
Antelepsin
Antilepsin
BAS 00308658
BIDD:PXR0144
BRN 0759557
C1277_SIGMA
C15H10ClN3O3
CHEBI:3756
CHEMBL452
CID2802
CLONAZEPAM
Chlonazepam
Cloazepam
Clonazepam (JP15/USP/INN)
Clonazepam [USAN:INN:BAN:JAN]
Clonazepamum
Clonazepamum [INN-Latin]
Clonex
Clonopin
D00280
D002998
DB01068
DEA No. 2737
 
DF2374250
DivK1c_000973
EINECS 216-596-2
HMS2093H22
HMS503C07
HSDB 3265
I14-1364
IDI1_000973
Iktorivil
Jsp003251
KBio1_000973
Kenoket
Klonopin
Klonopin (TN)
Klonopin Rapidly Disintegrating
LS-34156
LS-34260
Landsen
Lktorivil
Lonazep
Melzap
MolPort-001-729-088
NINDS_000973
NIOSH/DF2374250
NSC 179913
NSC179913
Oprea1_168772
Paxam
RO4023
Ravotril
Rivatril
Rivoril
Rivotril
Ro 4-8180
Ro 4023
Ro 5-4023
Ro 5-4023/B-7
Ro 54023
Ro-5-4023
Solfidin
UNII-5PE9FDE8GB
WLN: T67 GMV JN IHJ CNW KR BG
ZINC03813003
clonazepam
4
Paroxetineapproved, investigationalPhase 4, Phase 322861869-08-743815
Synonyms:
(-)-(3S,4R)-4-(P-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-(methylenedioxy)phenoxy)methyl)piperidine
(-)-(3S,4R)-4-(p-Fluorophenyl)-3-((3,4-methylenedioxy)phenoxy)methyl)piperidine
(-)-Paroxetine
(-)-trans-4-(4-Fluorophenyl)-3-(3,4-methylenedioxyphenoxymethyl)piperidine
(-)-trans-4-(p-fluorophenyl)-3-[[3,4-(methylenedioxy)phenoxy]methyl]-piperidine
(3S,4R)-3-(1,3-benzodioxol-5-yloxymethyl)-4-(4-fluorophenyl)piperidine
(3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
(3S-trans)-3-((1,3-Benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
(3S-trans)-3-((1,3-benzodioxol-5-yloxy)methyl)-4-(4-fluorophenyl)piperidine
(3S-trans)-3-[(1,3-Benzodioxol-5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine
110429-35-1
3-(Benzo[1,3]Dioxol-5-Yl-Oxymethyl)-4-(4-Fluoro-Phenyl)-Piperidine Hydrochloride
61869-08-7
63952-24-9
64006-44-6 (maleate)
78246-49-8 (hydrochloride)
AB00514724
AC1L2AKL
AC1Q1H18
AC1Q4LV6
Aropax
BIDD:GT0673
BPBio1_000949
BRD-K37991163-003-02-7
BRL 29060
BRL-29060
BSPBio_000861
C07415
C19H20FNO3
CHEBI:7936
CHEMBL490
CID43815
Casbol
D02362
DB00715
DivK1c_006884
FG 7051
FG-7051
FT-0085087
Frosinor
 
HMS2090H05
I14-7752
KBio1_001828
KBio2_002232
KBio2_004800
KBio2_007368
KBioSS_002232
LS-114249
MolPort-003-849-791
Motivan
NCGC00025355-02
NCGC00025355-03
NCGC00025355-04
NCGC00025355-05
NCGC00025355-06
NCGC00025355-07
NCGC00025355-08
NNC-20-7051
Paroxetina
Paroxetina [INN-Spanish]
Paroxetine
Paroxetine (TN)
Paroxetine (USP/INN)
Paroxetine Hcl
Paroxetine [USAN:INN:BAN]
Paroxetinum
Paroxetinum [INN-Latin]
PaxPar
Paxetil
Paxil
Paxil CR
Pexeva
Prestwick3_000851
Seroxat
Seroxat CR
SpecPlus_000788
Spectrum5_001665
Spectrum_001752
TL8003967
UNII-41VRH5220H
[3H]Paroxetine
paroxetine
5
DopamineapprovedPhase 4383651-61-6, 62-31-7681
Synonyms:
(3H)-Dopamine
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-Dihydroxyphenyl)ethylamine
2-(3,4-dihydroxyphenyl)ethylamine
2-benzenediol
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3,4-dihydroxyphenethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)-Pyrocatechol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-Aminoethyl)catechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
4-(2-aminoethyl)-pyrocatechol
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
ASL 279
BIDD:ER0506
BPBio1_001123
BSPBio_001932
Biomol-NT_000001
C03758
CHEBI:18243
CHEMBL59
CID681
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydroxytyramin
Hydroxytyramine
IDI1_000780
IP 498
Intropin
Intropin [*hydrochloride*]
KBio1_000780
 
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L-DOPAMINE
L000232
LDP
LS-159
Lopac-H-8502
Lopac0_000586
Medopa (TN)
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
SPECTRUM1505155
ST048774
STK301601
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
Spectrum_001012
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
a-(3,4-Dihydroxyphenyl)-b-aminoethane
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
cMAP_000036
cMAP_000065
dopamine
hydroxytyramine
intropin
m-Hydroxytyramine hydrochloride
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
6Serotonin Uptake InhibitorsPhase 4, Phase 31587
7Central Nervous System StimulantsPhase 42211
8Anti-Anxiety AgentsPhase 4, Phase 11885
9Tranquilizing AgentsPhase 4, Phase 14265
10AnticonvulsantsPhase 42695
11Central Nervous System DepressantsPhase 4, Phase 113403
12Serotonin AgentsPhase 4, Phase 33156
13Hypnotics and SedativesPhase 4, Phase 12616
14Antidepressive AgentsPhase 4, Phase 32736
15Antidepressive Agents, Second-GenerationPhase 4, Phase 31311
16GABA AgentsPhase 4, Phase 11684
17Cytochrome P-450 Enzyme InhibitorsPhase 4, Phase 33917
18
SerotoninPhase 4, Phase 3362750-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
19GABA ModulatorsPhase 4, Phase 1904
20Psychotropic DrugsPhase 4, Phase 3, Phase 16430
21Neurotransmitter Uptake InhibitorsPhase 4, Phase 33521
22Neurotransmitter AgentsPhase 4, Phase 3, Phase 118340
23Cytochrome P-450 CYP2D6 InhibitorsPhase 4, Phase 3727
24Lisdexamfetamine DimesylatePhase 498
25Dopamine AgentsPhase 43836
26Dopamine Uptake InhibitorsPhase 41331
27
CycloserineapprovedPhase 210868-41-7401, 6234
Synonyms:
(+)-4-Amino-3-isoxazolidinone
(+)-Cycloserine
(4R)-4-Amino-3-isoxazolidinone
(4R)-4-amino-1,2-oxazolidin-3-one
(4R)-4-aminoisoxazolidin-3-one
(R)-(+)-4-Amino-3-isoxazolidinone
(R)-(+)-Cycloserine
(R)-4-AMINO-ISOXAZOLIDIN-3-ONE
(R)-4-AMINO-isoxazolidin-3-one
(R)-4-Amino-3-isoxazolidinone
(R)-4-Amino-3-isoxazolidone
(R)-Cycloserine
1pb9
3-Isoxazolidinone, 4-amino-, (+)- (8CI)
3-Isoxazolidinone, 4-amino-, (4R)- (9CI)
3-Isoxazolidinone, 4-amino-, (R)
3-Isoxazolidinone, 4-amino-, D
30020_FLUKA
30020_SIGMA
4-27-00-05549 (Beilstein Handbook Reference)
4AX
68-41-7
AB00443920
AC-4721
AC1L1M33
AC1Q4UA7
AI3-50153
BB_NC-1631
BIDD:GT0707
BPBio1_001252
BRN 0080798
BSPBio_001138
BSPBio_002121
C 3909
C-9390
C-9400
C08057
C3909_SIGMA
C3H6N2O2
C6880_SIGMA
C7670_SIGMA
CAS-339-72-0
CAS-68-41-7
CHEBI:40009
CHEMBL771
CID6234
CPD-2482
CPD000058313
Cicloserina
Cicloserina [INN-Spanish]
Cicloserina [Italian]
Closerin
Closina
Cyclo-D-serine
Cyclorin
Cycloserine
Cycloserine (JP15/USP/INN)
Cycloserine [INN:BAN:JAN]
Cycloserinum
Cycloserinum [INN-Latin]
D-(+)-Cycloserine
D-4-Amino-3-isossazolidone
D-4-Amino-3-isossazolidone [Italian]
D-4-amino-3-Isoxazolidinone
D-4-amino-3-Isoxazolidone
D-4-amino-3-isoxazolidinone
D-4-amino-3-isoxazolidone
D-CS
D-Cycloserine
D-Cycloserine synth. BP 88
D-Cycloserine, synthetic
D-Oxamicina
D-Oxamycin
D-amino-3-isoxazolidinone
D-cycloserine
D00877
DB03123
DCS
DL-Cycloserine
DRG-0195
DivK1c_000098
E-733-A
EINECS 200-688-4
 
EU-0100252
FA6C7F8B-D080-4EA3-978F-1ECFB5A29D09
Farmiserina
HMS1571I20
HMS1920C06
HMS2051C15
HMS2091I14
HMS500E20
HSDB 3218
I-1431
IDI1_000098
K-300
KBio1_000098
KBio2_001340
KBio2_003908
KBio2_006476
KBio3_001341
KBioGR_000890
KBioSS_001340
L-Cycloserine
LMPK14000007
LS-86757
Lopac-C-1159
Lopac-C-3909
Lopac-C-7005
Lopac0_000252
MLS000758215
MLS001423962
Micoserina
Miroserina
Miroseryn
MolPort-000-858-643
NCGC00015213-01
NCGC00015213-02
NCGC00015213-03
NCGC00016306-01
NCGC00016306-02
NCGC00016306-03
NCGC00016306-05
NCGC00093713-01
NCGC00093713-02
NINDS_000098
NSC 154851
Novoserin
Orientomycin
Oxamicina
Oxamicina [Italian]
Oxamycin
PA 94
PA-94
Prestwick0_001089
Prestwick1_001089
Prestwick2_001089
Prestwick3_001089
R(+)-4-Amino-3-isoxazolidinone
R-(+)-Cycloserine
R-4-Amino-3-isoxazolidinone
RO-1-9213
Ro-1-9213
S1998_Selleck
SAM001247014
SAM002264599
SC-49088
SMP1_000167
SMR000058313
SPBio_000008
SPBio_003029
SPECTRUM1500215
Seromycin
Seromycin (TN)
Spectrum2_000084
Spectrum3_000371
Spectrum4_000305
Spectrum5_000797
Spectrum_000860
Tebemicina
Tisomycin
UNII-95IK5KI84Z
Wasserina
alpha-Cycloserine
cyclo-D-Serine
cycloserine
orientomycin
α-Cycloserine
28Renal AgentsPhase 2754
29AntimetabolitesPhase 212054
30Antitubercular AgentsPhase 21343
31Anti-Infective AgentsPhase 222062
32Anti-Bacterial AgentsPhase 211226
33Antibiotics, AntitubercularPhase 27180
34
Adenosineapproved, investigational41958-61-760961
Synonyms:
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-D-Ribofuranose
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-delta-Ribofuranose
1odi
2fqy
2gl0
30143-02-3
4-Aminopyrazolo[3,4-d]pyrimidine ribonucleoside
46946-45-6
46969-16-8
58-61-7
6-Amino-9-.beta.-ribofuranosyl-9H-purine
6-Amino-9-beta-D-ribofuranosyl-9H-purine
6-Amino-9beta-D-ribofuranosyl-9H-purine
6-Amino-9beta-delta-ribofuranosyl-9H-purine
9-(beta-D-Arabinofuranosyl)adenine
9-beta-D-Arabinofuranosyladenine
9-beta-D-Ribofuranosidoadenine
9-beta-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Ribofuranosyladenine
9-beta-delta-Arabinofuranosyladenine
9-beta-delta-Ribofuranosidoadenine
9-beta-delta-Ribofuranosyl-9H-purin-6-amine
9-beta-delta-Ribofuranosyladenine
9beta-D-Ribofuranosyladenine
9beta-D-ribofuranosyl-9H-Purin-6-amine
9beta-delta-Ribofuranosyladenine
9beta-delta-ribofuranosyl-9H-Purin-6-amine
A0152
A4036_SIGMA
A9251_SIGMA
AC1L1U8O
AC1Q1ID3
AC1Q52XU
ADN
AI3-52413
Ade-Rib
Ade-rib
Adenin riboside
Adenine 9-beta-D-arabinofuranoside
Adenine deoxyribonucleoside
Adenine nucleoside
Adenine riboside
Adenine-9-beta-D-ribofuranoside
Adenine-9beta-D-Ribofuranoside
Adenine-9beta-delta-Ribofuranoside
Adenocard
Adenocard (TN)
Adenocard, Adenosine
Adenocor
Adenoscan
Adenoscan (TN)
Adenosin
Adenosin [German]
Adenosina
Adenosine (JAN/USP)
Adenosine [USAN:BAN]
Adenosine, homopolymer
Adenosinum
Adensoine
Adenyldeoxyriboside
Ado
Adénosine
BB_NC-0565
BSPBio_001796
Bio1_000437
 
Bio1_000926
Bio1_001415
Boniton
C00212
CCRIS 2557
CHEBI:16335
CHEMBL477
CID60961
Caswell No. 010B
D000241
D00045
DB00640
Deoxyadenosine
Desoxyadenosine
EA6C60C2-6AFB-4264-A2F0-541373DB950E
EINECS 200-389-9
FT-0082881
HMS1920A13
HMS2091G13
KBio3_001296
LS-15085
MEDR-640
MLS000069638
MLS002153227
MolPort-001-838-229
Myocol
NCGC00023673-03
NCGC00023673-04
NCGC00023673-05
NCGC00023673-06
NCGC00023673-07
NSC 627048
NSC 7652
NSC627048
NSC7652
Nucleocardyl
Pallacor
Polyadenosine
Polyriboadenosine
S1647_Selleck
SDCCGMLS-0003108.P003
SMR000058216
SPBio_001194
SPECTRUM1500107
SR 96225
SR-96225
SUN-Y4001
Sandesin
Spectrum2_001257
Spectrum3_000288
TL8003749
UNII-K72T3FS567
USAF CB-10
V0098
Vidarabine
ZINC02169830
adenine-D-ribose
adenosine
b-D-Adenosine
beta-Adenosine
beta-D-Adenosine
beta-D-Ribofuranoside, adenine-9
beta-delta-Adenosine
bmse000061
nchembio.143-comp9
nchembio.186-comp109
nchembio.2007.56-comp13
nchembio.64-comp4
nchembio706-5
35
Citalopramapproved51259729-33-82771
Synonyms:
1,3-Dihydro-1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-5-isobenzofurancarbonitrile
1,3-dihydro[3,4]benzofuran-5-carbonitrile
1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
59729-33-8
AB00513896
AC-12214
AC1L1EFH
AE-641/00603021
Akarin
BPBio1_000929
BRD-A47598013-004-02-0
BSPBio_000843
Bonitrile
C07572
C20H21FN2O
CHEBI:3723
CHEMBL549
CID2771
CPD000465669
Celapram
Celexa
Celius
Ciazil
Cilift
Cipram
Cipramil
Ciprapine
Citabax
Citadur
Citadur (TN)
Citalec
Citalopram (USP/INN)
Citalopram Hydrobromide
Citalopram [Celexa]
Citalopram [INN:BAN]
Citalopram hydrobromide
Citalopramum
Citalopramum [INN-Latin]
 
Citol
Citopam
Citox
Citrol
Cytalopram
D07704
DB00215
Dalsan
EINECS 261-891-1
Elopram
HMS2090O09
HMS2093A14
Humorup
I01-0382
InChI=1/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3
L001223
LS-84327
Lopac0_000258
Lu 10-171
Lu-10-171
MolPort-003-666-794
NCGC00015267-07
NCGC00025160-02
Nitalapram
Oropram
Pramcit
Prestwick3_000692
Recital
SAM002589960
ST069372
STL058639
Seropram
Talam
Talohexal
Temperax
UNII-0DHU5B8D6V
Vodelax
Zentius
Zetalo
[3H]Citalopram
citalopram
36
Magnesium Sulfateapproved, vet_approved1797487-88-924083
Synonyms:
(C10-C16) Alkylalcohol sulfuric acid, magnesium salt
00627_FLUKA
10028-26-9
10034-99-8 (heptahydrate)
13143_RIEDEL
13143_SIAL
139939-75-6
18939-43-0
203726_ALDRICH
208094_SIAL
34276_FLUKA
34276_RIEDEL
38146_FLUKA
38146_RIEDEL
63126_FLUKA
63136_FLUKA
63136_SIAL
63139_FLUKA
63139_SIAL
68081-97-0
7487-88-9
AC1L2N76
AC1LAX36
AC1Q1U66
AI3-02029
Bitter salt
C10-C16 Alkyl alcohol sulfuric acid magnesium salt
CCRIS 8411
CHEBI:32599
CID24083
CPD0-2390
Caswell No. 534
D008278
DB00653
EINECS 231-298-2
EINECS 233-073-4
EINECS 242-691-3
EINECS 268-365-0
EPA Pesticide Chemical Code 050503
Epsom salt
HSDB 664
Hair salt
Heptahydrate Magnesium Sulfate
Kieserite [as monohydrate]
LS-88605
M2643_SIGMA
M3409_SIGMA
 
M7506_SIAL
M8150_SIGMA
MAGNESIUM SULFATE
Magnesium Sulfate In Plastic Container
Magnesium Sulfate, Heptahydrate
Magnesium Sulphate Hydrate
Magnesium bisulfate
Magnesium hydrogensulphate
Magnesium sulfate
Magnesium sulfate (1:1)
Magnesium sulfate anhydrous
Magnesium sulfate dried
Magnesium sulfate heptahydrate
Magnesium sulfate hexahydrate
Magnesium sulfate in dextrose 5% in plastic container
Magnesium sulfate solution
Magnesium sulphate
Magnesium sulphate anhydrous
Magnesium sulphate dried
Magnesium sulphate heptahydrate
Magnesium(II) sulfate
Magnesium(ii) sulfate
Magnesiumsulfat
MgSO4
MolPort-003-925-000
NSC 146179
OT-S
OT-S (drying agent)
SDA 15-062-07
Sal Angalis
Sal De sedlitz
Sal amarum
Sal anglicum
Sal catharticum
Sal seidlitense
Salts of england
Sel d'angleterre
Sulfate, Magnesium
Sulfuric acid magnesium salt
Sulfuric acid magnesium salt (1:1)
Sulfuric acid magnesium salt (VAN)
Sulfuric acid, C10-16 alkyl ester, magnesium salt
Sulfuric acid, magnesium salt
Sulfuric acid, magnesium salt (1:1)
Sulfuric acid, mono-C10-16-alkyl esters, magnesium salts
Tomix OT
UNII-DE08037SAB
UNII-ML30MJ2U7I
magnesium(2+) ion sulfate
37
Caffeineapproved, Nutraceutical39658-08-22519
Synonyms:
07E4FB58-FD79-4175-8E3D-05BF96954522
1,3,7-Trimethyl-2,6-dioxopurine
1,3,7-Trimethyl-3,7-dihydro-1H-purine-2,6-dione
1,3,7-Trimethylpurine-2,6-dione
1,3,7-Trimethylxanthine
1,3,7-trimethyl-2,6-dioxopurine
1,3,7-trimethylpurine-2,6-dione
1,3,7-trimethylxanthine
1-3-7-TRIMETHYLXANTHINE
1-Methyl-Theobromine
1-methyltheobromine
137X
1gfz
1l5q
1l7x
27602_FLUKA
2a3b
3,7-Dihydro-1,3,7-trimethyl-1H-purin-2,6-dion
3,7-Dihydro-1,3,7-trimethyl-1H-purine-2,6-dione
3,7-dihydro-1,3,7-trimethyl-1H-purine
5-26-13-00558 (Beilstein)
58-08-2
7-Methyl Theophylline
7-Methyltheophylline
7-methyltheophylline
71701-02-5
75035_FLUKA
95789-13-2
A.S.A. and Codeine Compound
AC-12774
AC1L1DV2
AC1Q3Z23
ACon1_000085
AI3-20154
AKOS000121334
Alert-Pep
Alert-pep
Anacin Maximum Strength
Anhydrous caffeine
Anhydrous caffeine (JP15)
Anhydrous caffeine (TN)
Anoquan
BIDD:ER0554
BIDD:GT0632
BIDD:PXR0172
BIM-0050216.0001
BRD-K02404261-001-02-7
BRD-K02404261-001-03-5
BRN 0017705
BSPBio_001921
Berlin-Chemie Brand of Caffeine
Bio-0579
Bio1_000473
Bio1_000962
Bio1_001451
Bristol-Myers Squibb Brand of Caffeine
C 0750
C07481
C0750_SIAL
C1778_SIAL
C2042
C6035_FLUKA
C6035_SIGMA
C7731_SIAL
C8960_SIAL
CCRIS 1314
CFF
CHEBI:27732
CHEMBL113
CID2519
CU-01000012617-3
Cafamil
Cafcit
Cafecon
Cafeina
Cafergot
Cafeína
Caffedrine
Caffedrine Caplets
Caffein
Caffeina
Caffeina [Italian]
Caffeine (USP)
Caffeine (natural)
Caffeine Pure
Caffeine [BAN:JAN]
Caffeine solution
Caffeine, Anhydrous
Caffeine, Monohydrate
Caffeine, Synthetic
Caffeine, anhydrous
Caffeine, synthetic
Caffeinum
Caffine
Cafipel
Caféine
Coffein
Coffein [German]
Coffeine
Coffeinum
Coffeinum N
Coffeinum Purrum
Compound 65
D002110
D00528
DB00201
DHC Plus
DHCplus
Darvon Compound
Darvon Compound-65
Dasin
Dexitac
Dexitac Stay Alert Stimulant
Dhc Plus
Diurex
DivK1c_000730
Durvitan
EINECS 200-362-1
EU-0100228
Eldiatric C
Enerjets
Ercatab
Esgic
Esgic-Plus
FEMA No. 2224
Femcet
Fioricet
Fiorinal
GlaxoSmithKline Brand of Caffeine
Guaranine
HMS1920I09
HMS2091O11
HMS502E12
HSDB 36
Hycomine
Hycomine Compound
I14-4386
 
IDI1_000730
Invagesic
Invagesic Forte
KBio1_000730
KBio2_001781
KBio2_004349
KBio2_006917
KBio3_001141
KBioGR_002325
KBioSS_001781
Keep Alert
Kofein
Kofein [Czech]
Koffein
Koffein [German]
L000155
LS-237
Lanorinal
Lopac-C-0750
Lopac0_000228
MEGxp0_001350
MLS001055341
MLS001056714
MLS001066409
Mateina
Mateína
Maximum Strength Snapback Stimulant Powders
Medigesic Plus
Merck dura Brand of Caffeine
Methyltheobromide
Methyltheobromine
Methylxanthine theophylline
Midol Maximum Strength
Migergot
Miudol
MolMap_000054
MolPort-000-730-850
Monohydrate Caffeine
Monomethyl Derivative of Theophylline
Monomethyl derivative of Theophylline
NCGC00015208-01
NCGC00015208-02
NCGC00015208-04
NCGC00015208-14
NCGC00090699-01
NCGC00090699-02
NCGC00090699-03
NCGC00090699-04
NCGC00090699-05
NCGC00090699-06
NCGC00090699-07
NCGC00090699-08
NCGC00090699-09
NCGC00168808-01
NCGC00168808-02
NCI-C02733
NCIOpen2_008255
NINDS_000730
NSC 5036
NSC5036
Natural Caffeinum
Nix Nap
No Doz
No-Doz
Nodaca
Nodoz Maximum Strength Caplets
Norgesic
Norgesic Forte
Organex
Orphengesic
Orphengesic Forte
P-A-C Analgesic Tablets
PDSP1_001016
PDSP1_001235
PDSP2_001000
PDSP2_001219
Passauer Brand of Caffeine
Pep-Back
Percoffedrinol N
Percutafeine
Phensal
Pierre Fabre Brand of Caffeine
Probes1_000150
Probes2_000128
Propoxyphene
Propoxyphene Compound 65
Propoxyphene Compound-65
Quick Pep
Quick-Pep
Refresh'n
Republic Drug Brand of Caffeine
SDCCGMLS-0064595.P001
SDCCGMLS-0064595.P002
SK 65 Compound
SK-65 Compound
SMR000326667
SPBio_001222
SPECTRUM1500155
STK177283
Seid Brand of Caffeine
Spectrum2_001261
Spectrum3_000321
Spectrum4_001782
Spectrum5_000423
Spectrum_001301
Stim
Synalgos-Dc
TNP00310
Thein
Theine
Theobromine ME
Theobromine Me
Theophylline ME
Theophylline Me
Theophylline, 7-methyl
Thompson Brand 1 of Caffeine
Thompson Brand 2 of Caffeine
Tirend
Tri-Aqua
Triad
UNII-3G6A5W338E
Ultra Pep-Back
Vivarin
W222402_ALDRICH
WLN: T56 BN DN FNVNVJ B1 F1 H1
Wake-Up
Wigraine
Xanthine, 1,3,7-trimethyl
ZINC00001084
bmse000206
cafeine
caffeine
caffenium
component of Cafergot
nchembio.243-comp7
nchembio.63-comp5
nchembio774-comp2
teina
teína
38Anti-Arrhythmia Agents3093
39Purinergic P1 Receptor Antagonists360
40Vasodilator Agents3543
41Analgesics11733
42Phosphodiesterase Inhibitors1289
43Parasympatholytics1085
44Autonomic Agents10150
45Antiparkinson Agents1574
46Cholinergic Agents3992
47Cholinergic Antagonists1706
48Muscarinic Antagonists1166
49Peripheral Nervous System Agents23689

Interventional clinical trials:

(show top 50)    (show all 57)
idNameStatusNCT IDPhase
1Long Term Treatment of Panic Disorder With Clonazepam or ParoxetineCompletedNCT02852577Phase 4
2A Study Of Sertraline Compared With Paroxetine In The Treatment Of Panic DisorderCompletedNCT00677352Phase 4
3Paroxetine vs Placebo Combined With Aerobic Exercise or Relaxation in Panic DisorderCompletedNCT00540098Phase 4
4Sertraline in Generalized Social Phobia With Co-Occurring Anxiety and Mood DisordersActive, not recruitingNCT00182533Phase 4
5Lisdexamfetamine Dimesylate in the Treatment of Adult ADHD With Anxiety Disorder ComorbidityActive, not recruitingNCT01863459Phase 4
6A Study To Assess the Safety of Extended Release Alprazolam for the Treatment of Adolescents With Panic Disorder or Anxiety With Panic AttacksTerminatedNCT00634790Phase 4
7Mechanisms of Panic Disorders TreatmentUnknown statusNCT01323556Phase 2, Phase 3
8Psychotherapy Outcome and Self-selection Effects in Panic DisorderUnknown statusNCT01606592Phase 2, Phase 3
9Virtual Reality Exposure Therapy in Agoraphobic ParticipantsCompletedNCT00734370Phase 2, Phase 3
10Treatment of Panic Disorder: Long Term StrategiesCompletedNCT00000368Phase 3
11Comparison of Psychotherapy Programs to Treat Panic DisorderCompletedNCT00353470Phase 3
12Internet-Versus Group-Administered Cognitive Behavior Therapy for Panic DisorderCompletedNCT00845260Phase 3
13Treatment of Social Phobia and Panic Disorder in AdultsCompletedNCT00619138Phase 3
14Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical HeterophoriaCompletedNCT00785135Phase 3
15Trans-diagnostic Group CBT vs. Standard Group CBT for Depression, Social Anxiety and Agoraphobia/Panic DisorderNot yet recruitingNCT02954731Phase 2, Phase 3
16Augmentation of Psychotherapy With D-Cycloserine in AgoraphobiaCompletedNCT01928823Phase 2
17Effectiveness of Intensive Cognitive Behavioral Therapy in Treating Adolescent Panic Disorder and AgoraphobiaCompletedNCT00576719Phase 2
18Physical Exercise Versus Cognitive-behavioral Therapy (CBT) for Panic Disorders: A Randomised Controlled TrialCompletedNCT01076777Phase 2
19Exposure Therapy for Fear of Falling in Older AdultsCompletedNCT01609322Phase 2
20Effectiveness of Cognitive Behavioral Therapy With Panic Control Treatment for Adolescents With Panic DisorderCompletedNCT00705380Phase 2
21Cognitive Behavior Therapy vs Exposure in Vivo in the Treatment of Panic Disorder With AgoraphobiaRecruitingNCT01680237Phase 2
22Improve: Integrating Emotion Focused Components Into Psychological TherapyRecruitingNCT02822443Phase 2
23The Modular Protocol for Mental Health (MPMH)Not yet recruitingNCT03143634Phase 1, Phase 2
24An Bioequivalence Study Of Xanax Extended Release Tablets From Two Different Manufacturing SitesCompletedNCT01330472Phase 1
25Study of Virtual Reality Therapy and Cognitive Behavior Therapy in Panic Disorder With AgoraphobiaUnknown statusNCT00129610
26Thought Field Therapy and Cognitive Therapy for AgoraphobiaCompletedNCT00932919
27Longterm Outcome of Inpatient Cognitive and Behavioral Therapies for AgoraphobiaCompletedNCT01446172
28Physical Activity and Cognitive Behavioural Therapy in Panic Disorder and AgoraphobiaCompletedNCT01928810
29Cognitive Behavioral Therapy in Panic DisorderCompletedNCT00772746
30Physical Activity and Cognitive Behavioural Therapy in Panic DisorderCompletedNCT01788800
31Vestibular Dysfunction In Adult Patients With Panic Disorder With or Without AgoraphobiaCompletedNCT00004367
32Can Thought Field Therapy (TFT) be Helpful for Patients With an Anxiety Disorder?CompletedNCT00202709
33Pilot Study of Vestibular Rehabilitation Training for Panic Disorder With Vestibular DysfunctionCompletedNCT00004366
34Cognitive Behavior Psychotherapy in Panic DisorderCompletedNCT01025908
35Interpretation Modification Program for Social PhobiaCompletedNCT00684541
36Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six MonthsCompletedNCT00711737
37Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid SyndromeCompletedNCT02833194
38Genetic Causes of Panic DisorderCompletedNCT00083265
39Youth Mayo Clinic Anxiety Coach Pilot StudyCompletedNCT02205177
40Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the ElderlyCompletedNCT02387047
41Internet-based Exposure Therapy for Panic DisorderRecruitingNCT03061448
42Clinical Trial of Transdiagnostic Cognitive-Behavior Therapy for Anxiety DisordersRecruitingNCT02811458
43Providing Tools for Effective Care and Treatment of Anxiety DisordersRecruitingNCT02605668
44Effectiveness of a Transdiagnostic Internet-based Treatment for Emotional DisordersRecruitingNCT02345668
45Virtual Reality and Concept of Control in the Treatment of AcrophobiaRecruitingNCT02020824
46Efficacy of a Transdiagnostic Internet-based Protocol in Community SampleRecruitingNCT02578758
47Examining the Effects of Reduced Environmental Stimulation on AnxietyRecruitingNCT03051074
48Building an Outcomes Assessment Infrastructure to Assess Anxiety TreatmentRecruitingNCT02305537
49Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric AnxietyRecruitingNCT02810171
50Expectation of Unpleasant Events in Anxiety DisordersRecruitingNCT00055224

Search NIH Clinical Center for Agoraphobia

Inferred drug relations via UMLS68/NDF-RT46:


Cochrane evidence based reviews: agoraphobia

Genetic Tests for Agoraphobia

About this section

Anatomical Context for Agoraphobia

About this section

MalaCards organs/tissues related to Agoraphobia:

36
Cortex, Thyroid, Brain, Pituitary, Cingulate cortex, Amygdala

Publications for Agoraphobia

About this section

Articles related to Agoraphobia:

(show top 50)    (show all 545)
idTitleAuthorsYear
1
Reduction in Costs after Treating Comorbid Panic Disorder with Agoraphobia and Generalized Anxiety Disorder. (28418834)
2017
2
Burden and Distress in Caregivers of Patients With Panic Disorder and Agoraphobia. (27861457)
2017
3
Psychoticism in patients with panic disorder with or without comorbid agoraphobia. (28345374)
2017
4
Threat expectancy bias and treatment outcome in patients with panic disorder and agoraphobia. (27061246)
2016
5
Insomnia Symptoms Following Treatment for Comorbid Panic Disorder With Agoraphobia and Generalized Anxiety Disorder. (27019339)
2016
6
The role of treatment delivery factors in exposure-based cognitive behavioral therapy for panic disorder with agoraphobia. (27235836)
2016
7
Agoraphobia Related to Unassertiveness in Panic Disorder. (26915016)
2016
8
A Comparison of Psychoanalytic Therapy and Cognitive Behavioral Therapy for Anxiety (Panic/Agoraphobia) and Personality Disorders (APD Study): Presentation of the RCT Study Design. (27594602)
2016
9
Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults. (27730622)
2016
10
Predictors of Dropout From Cognitive-Behavioral Group Treatment for Panic Disorder With Agoraphobia: An Exploratory Study. (27385412)
2016
11
Psychological therapies for panic disorder with or without agoraphobia in adults: a network meta-analysis. (27071857)
2016
12
Platzschwindel, agoraphobia and their influence on theories of anxiety at the end of the nineteenth century: theories of the role of biology and 'representations' (Vorstellungen). (27450798)
2016
13
Agoraphobia With and Without Panic Disorder: A 20-Year Follow-up of Integrated Exposure and Psychodynamic Therapy. (26588081)
2016
14
Cognitive Models for Panic Disorder With Agoraphobia: A Study of Disaggregated Within-Person Effects. (27123977)
2016
15
Sustained Resolution of Panic Disorder, Agoraphobia, and Generalized Anxiety Disorder With a Single Ketamine Infusion: A Case Report. (27828703)
2016
16
A discussion of various aspects of panic disorder depending on presence or absence of agoraphobia. (27423353)
2016
17
Panic disorder with agoraphobia from a behavioral neuroscience perspective: Applying the research principles formulated by the Research Domain Criteria (RDoC) initiative. (26877119)
2016
18
SECOND-STAGE TREATMENTS FOR RELATIVE NONRESPONDERS TO COGNITIVE BEHAVIORAL THERAPY (CBT) FOR PANIC DISORDER WITH OR WITHOUT AGORAPHOBIA-CONTINUED CBT VERSUS SSRI: A RANDOMIZED CONTROLLED TRIAL. (26663632)
2016
19
Facing the fear - clinical and neural effects of cognitive behavioural and pharmacotherapy in panic disorder with agoraphobia. (26837851)
2016
20
Agency and Anxiety: Delusions of Control and Loss of Control in Schizophrenia and Agoraphobia. (27725796)
2016
21
The Mobility Inventory for Agoraphobia Avoidance Alone Scale: Factor Structure and Psychometric Properties of Subscales. (27449053)
2016
22
Predictors of the application of exposure in vivo in the treatment of agoraphobia in an outpatient clinic: An exploratory approach. (26308791)
2015
23
Intensive behavioral therapy for agoraphobia. (25479049)
2015
24
Agoraphobia and Melancholia: Thoughts on Milrod's "Emptiness in Agoraphobia Patients". (26263925)
2015
25
A systematic review of predictors and moderators of improvement in cognitive-behavioral therapy for panic disorder and agoraphobia. (26443228)
2015
26
Frontal cortex absolute beta power measurement in Panic Disorder with Agoraphobia patients. (26093831)
2015
27
An admixture analysis of age of onset in agoraphobia. (25898330)
2015
28
The combined use of virtual reality exposure in the treatment of agoraphobia. (26150057)
2015
29
Social Anxiety Disorder and Agoraphobia in Dermatology Patients; Two Cases and a Review of the Literature. (25721467)
2015
30
Association of human microRNAs miR-22 and miR-491 polymorphisms with panic disorder with or without agoraphobia in a Korean population. (26361067)
2015
31
CLINICAL CONSEQUENCES OF THE REVISED DSM-5 DEFINITION OF AGORAPHOBIA IN TREATMENT-SEEKING ANXIOUS YOUTH. (25845579)
2015
32
Evidence for chronic low-grade systemic inflammation in individuals with agoraphobia from a population-based prospective study. (25875094)
2015
33
Panic disorder and agoraphobia: A direct comparison of their multivariate comorbidity patterns. (26480214)
2015
34
Predictors of short- and long-term avoidance in completers of inpatient group interventions for agoraphobia. (25917291)
2015
35
Ghrelin and lipid levels in panic disorder before and after treatment and their relationship with agoraphobia. (26400133)
2015
36
Metabolic decoupling in daily life in patients with panic disorder and agoraphobia. (26028550)
2015
37
Treating Treatment-Resistant Patients with Panic Disorder and Agoraphobia Using Psychotherapy: A Randomized Controlled Switching Trial. (25722042)
2015
38
Cognitive and Guided Mastery Therapies for Panic Disorder with Agoraphobia: 18-Year Long-Term Outcome and Predictors of Long-Term Change. (25452222)
2014
39
The neural representation of emotionally neutral faces and places in patients with panic disorder with agoraphobia. (24176537)
2014
40
Two-year course of generalized anxiety disorder, social anxiety disorder, and panic disorder with agoraphobia in a sample of latino adults. (24731232)
2014
41
Therapygenetics: anterior cingulate cortex-amygdala coupling is associated with 5-HTTLPR and treatment response in panic disorder with agoraphobia. (25223844)
2014
42
Panic disorder and agoraphobia: an overview and commentary on DSM-5 changes. (24865357)
2014
43
The relationships among separation anxiety disorder, adult attachment style and agoraphobia in patients with panic disorder. (25218272)
2014
44
Does rTMS alter neurocognitive functioning in patients with panic disorder/agoraphobia? An fNIRS-based investigation of prefrontal activation during a cognitive task and its modulation via sham-controlled rTMS. (24757668)
2014
45
Altered top-down and bottom-up processing of fear conditioning in panic disorder with agoraphobia. (23611156)
2014
46
Evaluation of a practice team-supported exposure training for patients with panic disorder with or without agoraphobia in primary care - study protocol of a cluster randomised controlled superiority trial. (24708672)
2014
47
The role of safety behaviors in exposure-based treatment for panic disorder and agoraphobia: associations to symptom severity, treatment course, and outcome. (25445073)
2014
48
Therapist effects and the outcome-alliance correlation in cognitive behavioral therapy for panic disorder with agoraphobia. (24275067)
2014
49
Cognitive-behavioral therapy for panic disorder with agoraphobia in older people: a comparison with younger patients. (24867666)
2014
50
Constraint and loneliness in agoraphobia: An empirical investigation. (25367660)
2014

Variations for Agoraphobia

About this section

Expression for genes affiliated with Agoraphobia

About this section
Search GEO for disease gene expression data for Agoraphobia.

Pathways for genes affiliated with Agoraphobia

About this section

GO Terms for genes affiliated with Agoraphobia

About this section

Cellular components related to Agoraphobia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1neuron projectionGO:00430058.6OPRK1, SLC6A2, SLC6A4, STMN1
2integral component of plasma membraneGO:00058878.2CCKBR, GRPR, HTR1A, OPRK1, PTK7, SLC6A2
3integral component of membraneGO:00160217.8CCKBR, GRPR, HTR1A, MAOA, OPRK1, PTK7
4membraneGO:00160207.2CCKBR, GRPR, HTR1A, MAOA, OPRK1, PTK7

Biological processes related to Agoraphobia according to GeneCards Suite gene sharing:

(show all 10)
idNameGO IDScoreTop Affiliating Genes
1behaviorGO:000761010.4HTR1A, OPRK1
2dopamine uptake involved in synaptic transmissionGO:005158310.3SLC6A2, SLC6A4
3monoamine transportGO:001584410.3SLC6A2, SLC6A4
4neurotransmitter transportGO:000683610.3SLC6A2, SLC6A4
5sensory perceptionGO:000760010.2CCKBR, OPRK1
6social behaviorGO:003517610.1GRPR, SLC6A4
7digestionGO:00075869.9CCKBR, PIR
8vasoconstrictionGO:00423109.9HTR1A, SLC6A4
9phospholipase C-activating G-protein coupled receptor signaling pathwayGO:00072009.8CCKBR, GRPR, OPRK1
10signal transductionGO:00071658.4CCKBR, GRPR, HTR1A, OPRK1, PTK7, STMN1

Molecular functions related to Agoraphobia according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1dopamine:sodium symporter activityGO:000533010.2SLC6A2, SLC6A4
2monoamine transmembrane transporter activityGO:00085049.5SLC6A2, SLC6A4
3G-protein coupled receptor activityGO:00049309.0CCKBR, GRPR, HTR1A, OPRK1

Sources for Agoraphobia

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet